研究概要
通过在我们的研究中利用NK细胞标记基因,我们开发了一个能够预测患者临床结局和治疗策略的新特征。
研究思路结论见上方概要
背景
作为固有免疫系统的效应细胞,NK 细胞(NK细胞)在肿瘤免疫治疗反应和临床结局中发挥着重要作用。
方法
在我们的研究中,我们从TCGA和GEO队列中收集了卵巢癌样本,共纳入1793个样本。此外,还纳入了四个高级别浆液性卵巢癌scRNA-seq数据,用于筛选NK细胞标记基因。加权基因共表达网络分析(WGCNA)识别了与NK细胞相关的核心模块和中心基因。采用“TIMER”、“CIBERSORT”、“MCPcounter”、“xCell”和“EPIC”算法预测每个样本中不同免疫细胞类型的浸润特征。使用LASSO-COX算法构建风险模型以预测预后。最后,进行了药物敏感性筛选。
结果
我们首先对每个样本的NK细胞浸润进行评分,发现NK细胞浸润水平影响卵巢癌患者的临床结局。因此,我们分析了四个高级别浆液性卵巢癌scRNA-seq数据,在单细胞水平筛选NK细胞标记基因。WGCNA算法基于bulk RNA转录组模式筛选NK细胞标记基因。最终,共有42个NK细胞标记基因纳入我们的研究。其中,14个NK细胞标记基因随后用于构建meta-GPL570队列的14基因预后模型,将患者分为高风险和低风险亚组。该模型的预测性能已在不同外部队列中得到充分验证。肿瘤免疫微环境分析显示,预后模型的高风险评分与M2巨噬细胞、癌相关成纤维细胞、造血干细胞、基质评分呈正相关,与NK细胞、细胞毒性评分、B细胞和T细胞CD4+Th1呈负相关。此外,我们发现博来霉素、顺铂、多西他赛、多柔比星、吉西他滨和依托泊苷在高风险组中更有效,而紫杉醇对低风险组患者具有更好的治疗效果。
展开英文摘要原文
BACKGROUND: As an innate immune system effector, natural killer cells (NK cells) play a significant role in tumor immunotherapy response and clinical outcomes.
METHODS: In our investigation, we collected ovarian cancer samples from TCGA and GEO cohorts, and a total of 1793 samples were included. In addition, four high-grade serous ovarian cancer scRNA-seq data were included for screening NK cell marker genes. Weighted gene coexpression network analysis (WGCNA) identified core modules and central genes associated with NK cells. The "TIMER," "CIBERSORT," "MCPcounter," "xCell," and "EPIC" algorithms were performed to predict the infiltration characteristics of different immune cell types in each sample. The LASSO-COX algorithm was employed to build risk models to predict prognosis. Finally, drug sensitivity screening was performed.
RESULTS: We first scored the NK cell infiltration of each sample and found that the level of NK cell infiltration affected the clinical outcome of ovarian cancer patients. Therefore, we analyzed four high-grade serous ovarian cancer scRNA-seq data, screening NK cell marker genes at the single-cell level. The WGCNA algorithm screens NK cell marker genes based on bulk RNA transcriptome patterns. Finally, a total of 42 NK cell marker genes were included in our investigation. Among which, 14 NK cell marker genes were then used to develop a 14-gene prognostic model for the meta-GPL570 cohort, dividing patients into high-risk and low-risk subgroups. The predictive performance of this model has been well-verified in different external cohorts. Tumor immune microenvironment analysis showed that the high-risk score of the prognostic model was positively correlated with M2 macrophages, cancer-associated fibroblast, hematopoietic stem cell, stromal score, and negatively correlated with NK cell, cytotoxicity score, B cell, and T cell CD4+Th1. In addition, we found that bleomycin, cisplatin, docetaxel, doxorubicin, gemcitabine, and etoposide were more effective in the high-risk group, while paclitaxel had a better therapeutic effect on patients in the low-risk group.
CONCLUSION: By utilizing NK cell marker genes in our investigation, we developed a new feature that is capable of predicting patients' clinical outcomes and treatment strategies.
论文信息
- 作者
- He X、Feng W
- 单位
- Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Huangpu District, Shanghai 200025, China.China
- 期刊
- Mediators of inflammation2023